The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interaction of HIV-1 Tat Protein with Heparin
Open accessAbstract
Human immunodeficiency virus type 1 (HIV-1) Tat protein is released from infected cells. Extracellular Tat enters the cell where it stimulates the transcriptional activity of HIV-long terminal repeat (LTR) and of endogenous genes. Heparin modulates the angiogenic (Albini, A., Benelli, R., Presta, M., Rusnati, M., Ziche, M., Rubartelli, A., Paglialunga, G., Bussolino, F., and Noonan, D. (1996) Oncogene 12, 289-297) and transcriptional (Mann, D. A., and Frankel, A. D. (1991) EMBO J. 10, 1733-1739) activity of extracellular Tat. Here we demonstrate that heparin binds specifically to recombinant HIV-1 Tat produced as glutathione S-transferase (GST) fusion protein and immobilized on glutathione-agarose beads. Heparin and heparan sulfate (HS), but not dermatan sulfate, chondroitin sulfates A and C, hyaluronic acid, and K5 polysaccharide, competed with 3H-labeled heparin for binding to immobilized GST-Tat and inhibited HIV-LTR transactivation induced by extracellular GST-Tat. Selective 2-O-, 6-O-, total-O-desulfation, or N-desulfation/N-acetylation dramatically reduced the capacity of heparin to bind GST-Tat. Totally-O-desulfated and 2-O-desulfated heparins also showed a reduced capacity to inhibit the transactivating activity of GST-Tat. Very low molecular weight heparins showed a significant decrease in their capacity to bind GST-Tat and to inhibit its LTR transactivating activity when compared with conventional 13.6-kDa heparin. However, when 3.0-kDa heparin was affinity chromatographed on immobilized GST-Tat to isolate binding and non-binding subfractions, the Tat-bound fraction was >/=1,000 times more potent than the unbound fraction in inhibiting the transactivating activity of GST-Tat. The results demonstrate that Tat interacts in a size-dependent manner with heparin/HS and that high affinity Tat-heparin interaction requires at least some 2-O-, 6-O-, and N-positions to be sulfated. The Tat binding activity of the glycosaminoglycans tested correlates with their capacity to affect the transactivating activity of extracellular Tat, indicating the possibility to design specific heparin/HS-like structures with Tat-antagonist activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the antithrombin-binding site in heparin.
Lindahl, U., Bäckström, G., Höök, M., Thunberg, L., Fransson, L. A., & Linker, A. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.7.3198 · Cited by 368
Cited by
The Structure of Glycosaminoglycans and their Interactions with Proteins
Gandhi, N. S., & Mancera, R. L. (2008) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2008.00741.x · Cited by 1,034
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., Ouidja, M. O., Brodsky, F. M., Marasa, J., Bagchi, D. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301440110 · Cited by 859
A Comprehensive Model for the Cellular Uptake of Cationic Cell‐penetrating Peptides
Duchardt, F., Fotin‐Mleczek, M., Schwarz, H., Fischer, R., & Brock, R. (2007) · Traffic · doi:10.1111/j.1600-0854.2007.00572.x · Cited by 771
Internalization of HIV-1 Tat Requires Cell Surface Heparan Sulfate Proteoglycans
Tyagi, M., Rusnati, M., Presta, M., & Giacca, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006701200 · Cited by 719
Self-citationPolyelectrolyte–protein complexes
Cooper, C. L., Dubin, P. L., Kayitmazer, A. B., & Turksen, S. (2005) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2005.05.007 · Cited by 674
Tat peptide-mediated cellular delivery: back to basics
BROOKS, H., LEBLEU, B., & VIVES, E. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.12.001 · Cited by 667
Sulfotransferases: Structure, Mechanism, Biological Activity, Inhibition, and Synthetic Utility
Chapman, E., Best, M. D., Hanson, S. R., & Wong, C. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200300631 · Cited by 543
Arginine‐rich cell‐penetrating peptides
Schmidt, N., Mishra, A., Lai, G. H., & Wong, G. C. L. (2010) · FEBS Letters · doi:10.1016/j.febslet.2009.11.046 · Cited by 521
Protein transduction technology
Wadia, J. S., & Dowdy, S. F. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00284-7 · Cited by 483
Delivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Nakase, I., Tadokoro, A., Kawabata, N., Takeuchi, T., Katoh, H., Hiramoto, K., Negishi, M., Nomizu, M., Sugiura, Y., & Futaki, S. (2007) · Biochemistry · doi:10.1021/bi0612824 · Cited by 429
WADIA, J., & DOWDY, S. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.005 · Cited by 428
Cell Penetrating Peptides: Intracellular Pathways and Pharmaceutical Perspectives
Patel, L. N., Zaro, J. L., & Shen, W.-C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9303-7 · Cited by 425
Liu, Y., Jones, M., Hingtgen, C. M., Bu, G., Laribee, N., Tanzi, R. E., Moir, R. D., Nath, A., & He, J. J. (2000) · Nature Medicine · doi:10.1038/82199 · Cited by 380
Mycroft-West, C. J., Su, D., Pagani, I., Rudd, T. R., Elli, S., Gandhi, N. S., Guimond, S. E., Miller, G. J., Meneghetti, M. C. Z., Nader, H. B., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1721319 · Cited by 361
TAT transduction: the molecular mechanism and therapeutic prospects
Gump, J. M., & Dowdy, S. F. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.002 · Cited by 356
Nakase, I., Takeuchi, T., Tanaka, G., & Futaki, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.006 · Cited by 342
Caveolae-Mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time
Ferrari, A., Pellegrini, V., Arcangeli, C., Fittipaldi, A., Giacca, M., & Beltram, F. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00122-9 · Cited by 335
Self-citationInfection of Human Dendritic Cells by Dengue Virus Causes Cell Maturation and Cytokine Production
Ho, L.-J., Wang, J.-J., Shaio, M.-F., Kao, C.-L., Chang, D.-M., Han, S.-W., & Lai, J.-H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1499 · Cited by 314
Intracellular targeting of polymer-bound drugs for cancer chemotherapy
NORI, A., & KOPECEK, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.10.006 · Cited by 303
Cell surface adherence and endocytosis of protein transduction domains
Lundberg, M., Wikström, S., & Johansson, M. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00135-7 · Cited by 301
Ziegler, A., Nervi, P., Dürrenberger, M., & Seelig, J. (2005) · Biochemistry · doi:10.1021/bi0491604 · Cited by 266
Ziegler, A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.005 · Cited by 255
Gonçalves, E., Kitas, E., & Seelig, J. (2006) · Biochemistry · doi:10.1021/bi052221t · Cited by 28
Capila, I., & Linhardt, R. J. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020201)41:3<390::aid-anie390>3.0.co;2-b
Metadata
- Authors
- Rusnati, M., Coltrini, D., Oreste, P., Zoppetti, G., Albini, A., Noonan, D., di Fagagna, F. D., Giacca, M., & Presta, M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-04
- Volume
- 272
- Issue
- 17
- Pages
- 11313-11320
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2081545569
- Cited by
- 196
- References
- 1
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.